Claim Missing Document
Check
Articles

Found 5 Documents
Search

STUDI IN SILICO METABOLIT SEKUNDER DALAM TANAMAN TAHONGAI (Kleinhovia hospita L.) SEBAGAI KANDIDAT AGEN TERAPI KARSINOMA HEPATOSELULER TERTARGET RESEPTOR c-MET (IN SILICO STUDY OF SECONDARY METABOLITES IN TAHONGAI PLANT(Kleinhovia hospita L.) AS A CANDIDATEFOR HEPATOCELLULER CARCINOMA THERAPEUTIC AGENT TARGETING c-MET RECEPTOR) Cahyaningrum, Lydia; Rubianti, Retno; Mahira, Tsania; Gabriel, Kevin; Rusdin, Agus; Novitasari, Dhania
Indonesian Journal of Pure and Applied Chemistry Vol 7, No 2 (2024)
Publisher : Tanjungpura University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26418/indonesian.v7i2.82567

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality in the world, mainly caused by chronic disease or virus. Prior studies have documented that the upregulation of c-MET can trigger the cancer progression, hence c-MET has been widely explored as target therapy for HCC. Tahongai plant (Kleinhovia hospita L.) has known to possess several biological effects, including anticancer activity. However, the molecular mechanism in this plant has not been studied yet. In this study, the bioactive constituents from Tahongai were evaluated based on the physicochemical features and molecular interaction in c-MET through in silico approaches. The druglikeness of each compound was checked through SwissADME, while the pharmacokinetic profile was predicted through preADMET webtool. The pharmacophore screening and molecular docking against c-MET were assessed using LigandScout and Autodock, respectively. Out of 14 selected compounds, only one (astragalin) did not pass the Lipinski rule, and most of the compounds demonstrated good ADMET profile. Eleutherol was choosen as the hit compound based on pharmacophore studies, and stibostemin G was potential to inhibit c-MET based on similar molecular interaction compared to its native ligand through molecular docking analysis. Further confirmation is urged to prove its anticancer effect from Tahongai against HCC, particulary targeting on c-MET
In Silico Study of Active Compounds in Guava Leaves (Psidium guajava L.) toward Angiotensin Converting Enzyme (ACE) as target for hypertension Hess, Aurelina Yunita; Ramadhani, Siti Zhahira; Andhryanti, Rifa Nurfadila; Zhafirah, Noor; Muljono, Fajar Oktavian; Fardhan, Firghi Muhammad; Novitasari, Dhania
Indonesian Journal of Chemical Science Vol. 13 No. 3 (2024): Indonesian Journal of Chemical Science
Publisher : Prodi Kimia

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hipertensi adalah suatu kondisi medis kronis yang terjadi ketika tekanan darah melebihi batas normal sehingga dapat meningkatkan risiko komplikasi penyakit lainnya seperti penyakit jantung. Pengobatan hipertensi saat ini sebagian besar menggunakan obat golongan Angiotensin Converting Enzyme (ACE) inhibitors. Salah satu bahan alam yang memiliki potensi menurunkan tekanan darah ialah daun jambu biji. Tujuan penelitian ini adalah mengevaluasi senyawa aktif yang terdapat pada daun jambu biji terhadap interaksi secara molekuler pada protein ACE dengan pendekatan studi in silico. Metode yang digunakan dalam pengujian ini meliputi karakteristik drug likeness berdasarkan kaidah Lipinski, prediksi profil ADMET, penapisan farmakofor, dan penambatan molekul. Hasil pengujian menunjukkan senyawa asam klorogenat dan luteolin yang terkandung pada daun jambu biji memiliki interaksi baik dengan protein target ACE berdasarkan energi ikatannya. Oleh karena itu, daun biji dapat dikembangkan lebih lanjut sebagai kandidat berbasis bahan alam untuk membantu dalam terapi hipertensi.
SENYAWA BIOAKTIF DARI DAUN MIANA SEBAGAI KANDIDAT PENGHAMBAT BETA-LAKTAMASE: STUDI KOMPUTASI Oktaviana, Lina; Moulana, Mohammad Zaeni; Rusdin, Agus; Lestari, Mila Ayu; Fathin, Nayla Maymuna; Novitasari, Dhania
Jurnal Insan Farmasi Indonesia Vol 7 No 3 (2024): Jurnal Insan Farmasi Indonesia
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/392s0e44

Abstract

Antibiotic resistance occurs through several mechanisms, one of which is  increase in beta-lactamase which can inactivate beta lactam antibiotics. The approach in finding new sources of antibiotics can be done by utilizing natural resources, one of which could be developed is miana leaves (Coleus scutellarioides). However, there has been no evaluation study related the antibacterial potential of the bioactive content  miana leaves against beta-lactam. This study analyzed the potential of bioactive compounds from miana leaves as beta-lactamase inhibitors through a computational approach. The methods used include physicochemical and pharmacokinetic profile prediction analysis, followed by pharmacophore screening and molecular docking. The results showed that most of the bioactive compounds of C. scutellarioides fulfill Lipinski's rule and show a good ADMET profile. Pharmacophore analysis produced the best model with an area under curve (AUC) score of 0.87. Molecular docking studies showed the compound 1-(4-phenylcyclohexyl)-1-hexanone had the highest binding affinity to beta-lactamase with a binding energy of -7.2 kcal/mol. This molecular interaction involves hydrogen bonding with amino acid residue GLU272 and van der Waals interaction toward ALA292 and TYR150. Therefore, bioactive compounds from miana leaves show potential as beta-lactamase inhibitors and open opportunities for the development of new antibacterial therapies based natural resources.
Rosmarinic Acid from Orthosiphon aristatus Potentially Targets Estrogen Receptor-Alpha in Breast Cancer: In-silico Study Qurrotaayun, Ghina Alya Putri; Sitompul, Joy Elizabeth Nauli; Fadhilah, Naya; Pramudita, Fransisca Widi; Putri, Nazwa Septiriana; Muljono, Fajar Oktavian; Fardhan, Firghi Muhammad; Novitasari, Dhania
Indonesian Journal of Cancer Chemoprevention Vol 15, No 2 (2024)
Publisher : Indonesian Society for Cancer Chemoprevention

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14499/indonesianjcanchemoprev15iss2pp150-161

Abstract

Breast cancer is the most common cancer among women. Tamoxifen, a widely used estrogen receptor-alpha (ER-α) inhibitor, is effective but often causes side effects, necessitating the search for alternative inhibitors from natural sources. Ortosiphon aristatus, also known as cat's whiskers, is a medicinal plant traditionally valued for its anti-inflammatory and antioxidant properties. Recent studies suggest its bioactive compounds may exhibit anticancer activity by inducing apoptosis in cancer cell lines. This study explores the potential of O. aristatus metabolites as ER-α inhibitors using computational approaches. Nine metabolites were assessed for their physicochemical properties based on Lipinski’s rule of five and ADMET predictions, followed by pharmacophore-based virtual screening with LigandScout and molecular docking with AutoDock. The results showed that all tested compounds complied with Lipinski’s rule, and most met ADMET criteria. Among these, rosmarinic acid was identified as one of the hit compounds based on pharmacophore screening, exhibiting binding interactions comparable to 4-hydroxytamoxifen with the ER-α amino acid residues HIS524 and GLY521. It also demonstrated a binding energy of -8.02 kcal/mol and a low inhibition constant (Ki) of 1.31 μM. These findings highlight the potential of O. aristatus and rosmarinic acid for further evaluation as candidates against ER-α in breast cancer cells.Keywords: breast cancer, estrogen receptor-alpha, Orthosiphon aristatus, in silico.
Confirmation of the potential mechanism of pentagamavunon-0 against temporomandibular arthritis using bioinformatic approaches Robin, Dwi Merry Christmarini; Ardhani, Retno; Novitasari, Dhania; Kusumawardani, Banun; Aulia Rahman, Faaza; Meiyanto, Edy; Purwanti, Nunuk
Dental Journal (Majalah Kedokteran Gigi) Vol. 58 No. 4 (2025): December
Publisher : Faculty of Dental Medicine, Universitas Airlangga https://fkg.unair.ac.id/en

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/j.djmkg.v58.i4.p367-375

Abstract

Background: Non-steroidal anti-inflammatory drugs (NSAID) are widely used in temporomandibular joint osteoarthritis management. However, the side effects of NSAIDs on multiple organs need to be anticipated. Curcumin is known for its anti-inflammatory and analgesic potential, comparable to that of NSAIDs. In a previous study, structurally modified curcumin increased the pharmacological effect and simultaneously reduced the toxicity and side effects of curcumin. Pentagamavunon-0 (PGV-0) is one of the active components synthesized by the structure modification of curcumin. Purpose: In this study, we identify the potential target of PGV-0 on the pathogenesis of temporomandibular arthritis characterized by inflammation. Methods: We used a bioinformatics approach to compare the PGV-0 target with curcumin and diclofenac sodium as controls. We identified overlapping gene targets of bioactive compounds (PGV-0, curcumin, or diclofenac sodium) retrieved from the SwissTargetPrediction and GeneCards platforms, specifically for temporomandibular arthritis. An interaction model among targets was developed using the STRING database and Gene Ontology Panther to expound on the bioactive compound’s function on the key signaling pathway. Finally, we formulated a molecular docking prediction between the bioactive compound and the target protein marker derived from the previous analysis using Molecular Operating Environment tools. Results: This study found that curcumin and PGV-0 targeted different molecular pathways in temporomandibular arthritis compared to diclofenac sodium. Curcumin and PGV-0 shared a similar pathway to curcumin by modulating metalloproteinases (MMPs), especially MMP-9 and MMP-13. Moreover, diclofenac sodium influenced cyclooxygenase metabolism. Conclusion: In this study, PGV-0 targeted metalloproteinase in temporomandibular arthritis pathogenesis. This finding underlines the PGV-0 advantage in preventing metalloproteinase-related tissue damage in temporomandibular arthritis.